HENDERSON, Nev.--(BUSINESS WIRE)--Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today financial results for the three-month period and year ended December 31, 2015.
“We had solid operating performance this quarter and our pipeline has never been stronger with multiple drugs enrolling in late-stage trials,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals. “We believe each of our late-stage drugs have demonstrated strong clinical data, and can be transformative to the Company. We just started enrolling the pivotal Phase 3 study for SPI-2012 and a Phase 2 study for poziotinib. We have two drugs lined up for FDA decision this year: Evomela in May, and EOquin in December. We remain focused on bringing innovative oncology medicines to the market.”
- SPI-2012, a novel long-acting GCSF: A pivotal Phase 3 study was initiated in Q1 2016 and will evaluate SPI-2012 as a treatment for chemotherapy-induced neutropenia in approximately 580 patients with breast cancer. In a Phase 2 dose ranging study, SPI-2012 was shown to have a shorter duration of severe neutropenia at the higher dose tested and comparable at the middle dose compared to the blockbuster drug pegfilgrastim. SPI-2012 was also shown to have an acceptable safety profile with no significant dose-related or unexpected toxicities.
- Poziotinib, a potential best-in-class, novel, pan-HER inhibitor: Spectrum initiated a Phase 2 breast cancer program in the U.S., based on promising Phase 1 efficacy data in breast cancer patients who had failed multiple other HER2-directed therapies. The Company submitted the Phase 2 protocol to the FDA as part of an Investigational New Drug (IND) application in November 2015. In addition, multiple Phase 2 studies are being conducted by Hanmi Pharmaceuticals and National OncoVenture in South Korea.
- EVOMELA, a propylene-glycol free melphalan formulation: After receiving a Complete Response Letter in October, Spectrum was granted a Type A meeting with the FDA on November 6, 2015. Within days, the company resubmitted the NDA and received a PDUFA date of May 9, 2016. If approved, we plan to launch Evomela with our existing sales force.
- EOquin, a potent tumor-activated drug for non-muscle invasive bladder cancer: Spectrum filed an NDA based on the previous Phase 3 studies. The FDA accepted the NDA and has given Spectrum a PDUFA date of December 11, 2016. The FDA also indicated that it plans to hold an advisory committee meeting regarding the NDA. The Company is actively enrolling an additional randomized, placebo-controlled Phase 3 trial under the SPA agreement. The Phase 3 study has been specifically designed to build on learnings from the previous EOquin Phase 3 studies, as well as recommendations from the FDA.
Three-Month Period Ended December 31, 2015 (All numbers are approximate)
Total product sales were $34.8 million in the fourth quarter of 2015. Total product sales decreased 33% from $51.7 million in the fourth quarter of 2014.
Product sales in the fourth quarter included: FUSILEV® (levoleucovorin) net sales of $15.1 million, FOLOTYN® (pralatrexate injection) net sales of $10.3 million, ZEVALIN® (ibritumomab tiuxetan) net sales of $3.7 million, BELEODAQ® (belinostat) for injection net sales of $3.0 million, and MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $2.7 million. FUSILEV sales exceeded our expectations in the fourth quarter, however, we continue to expect significant declines in the future due to additional competition and pricing pressure.
Spectrum recorded net loss of $4.2 million, or $0.06 per basic and diluted share in the three-month period ended December 31, 2015, compared to net loss of $3.0 million, or $0.05 per basic and diluted share in the comparable period in 2014. Total research and development expenses were $15.4 million in the quarter, as compared to $14.4 million in the same period in 2014. Selling, general and administrative expenses were $21.2 million in the quarter, compared to $24.5 million in the same period in 2014.
Spectrum recorded non-GAAP net loss of $4.6 million, or $0.07 per basic share and diluted share in the three-month period ended December 31, 2015, compared to non-GAAP net income of $7.5 million, or $0.12 per basic and $0.09 per diluted share in the comparable period in 2014. Non-GAAP research and development expenses were $14.8 million as compared to $14.0 million in the same period of 2014. Non-GAAP selling, general and administrative expenses were $18.1 million, as compared to $21.4 million in the same period in 2014.
Twelve-Month Period Ended December 31, 2015 (All numbers are approximate)
Total product sales were $136.9 million for the twelve months ended December 31, 2015. Total product sales decreased 27% from $186.5 million in the same period of 2014.
Product sales in 2015 included: FUSILEV® (levoleucovorin) net sales of $60.7 million, FOLOTYN® (pralatrexate injection) net sales of $40.6 million, ZEVALIN® (ibritumomab tiuxetan) net sales of $17.5 million, BELEODAQ® (belinostat) for injection net sales of $10.1 million, and MARQIBO® (vinCRIStine sulfate LIPOSOME injection) net sales of $8.0 million.
Spectrum recorded net loss of $50.8 million, or $0.78 per basic and diluted share in the twelve-month period ended December 31, 2015, compared to net loss of $45.7 million, or $0.71 per basic and diluted share in the comparable period in 2014. Total research and development expenses were $50.8 million for the year, as compared to $69.7 million in the same period in 2014. Selling, general and administrative expenses were $86.5 million for the year, compared to $97.4 million in the same period in 2014.
Spectrum recorded non-GAAP net loss of $17.6 million, or $0.27 per basic and diluted share in the twelve-month period ended December 31, 2015, compared to non-GAAP net income of $21.4 million, or $0.33 per basic and $0.27 per diluted share in the comparable period in 2014. Non-GAAP research and development expenses were $45.7 million as compared to $50.0 million in the same period of 2014. Non-GAAP selling, general and administrative expenses were $77.9 million, as compared to $84.9 million in the same period in 2014.
Wednesday, March 9, 2016 @ 4:30 p.m. Eastern/1:30 p.m. Pacific
|Domestic:||(877) 837-3910, Conference ID# 51999726|
|International:||(973) 796-5077, Conference ID# 51999726|
This conference call will also be webcast. Listeners may access the webcast, which will be available on the investor relations page of Spectrum Pharmaceuticals' website: www.sppirx.com on March 9, 2016 at 4:30 p.m. Eastern/1:30 p.m. Pacific.
About Spectrum Pharmaceuticals, Inc.
Spectrum Pharmaceuticals is a leading biotechnology company focused on acquiring, developing, and commercializing drug products, with a primary focus in Hematology and Oncology. Spectrum currently markets five hematology/oncology drugs, and expects two FDA decisions in 2016. Spectrum's strong track record for in-licensing and acquiring differentiated drugs, and expertise in clinical development have generated a robust, diversified, and growing pipeline of product candidates in Phase 2 and Phase 3 studies. More information on Spectrum is available at www.sppirx.com.
Forward-looking statement - This press release may contain forward-looking statements regarding future events and the future performance of Spectrum Pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially. These statements are based on management's current beliefs and expectations. These statements include, but are not limited to, statements that relate to our business and its future, including certain company milestones, Spectrum's ability to identify, acquire, develop and commercialize a broad and diverse pipeline of late-stage clinical and commercial products, leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy, and any statements that relate to the intent, belief, plans or expectations of Spectrum or its management, or that are not a statement of historical fact. Risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective, the possibility that our existing and new applications to the FDA and other regulatory agencies may not receive approval in a timely manner or at all, the possibility that our existing and new drug candidates, if approved, may not be more effective, safer or more cost efficient than competing drugs, the possibility that our efforts to acquire or in-license and develop additional drug candidates may fail, our lack of sustained revenue history, our limited marketing experience, our dependence on third parties for clinical trials, manufacturing, distribution and quality control and other risks that are described in further detail in the Company's reports filed with the Securities and Exchange Commission. We do not plan to update any such forward-looking statements and expressly disclaim any duty to update the information contained in this press release except as required by law.
SPECTRUM PHARMACEUTICALS, INC. ®, FUSILEV®, FOLOTYN®, ZEVALIN®, MARQIBO®, BELEODAQ® and EOquin® are registered trademarks of Spectrum Pharmaceuticals, Inc. and its affiliates. REDEFINING CANCER CARE™, EVOMELA™ and the Spectrum Pharmaceuticals' logos are trademarks owned by Spectrum Pharmaceuticals, Inc. Any other trademarks are the property of their respective owners.
© 2016 Spectrum Pharmaceuticals, Inc. All Rights Reserved
|SPECTRUM PHARMACEUTICALS, INC.|
|Condensed Consolidated Statements of Operations|
(In thousands, except per share amounts)
Three Months Ended
Twelve Months Ended
|Product sales, net||$||34,837||$||51,670||$||136,851||$||186,537|
|License fees and service revenue||15,494||191||25,705||293|
|Operating costs and expenses:|
|Cost of product sales (excludes amortization and impairment of intangible assets)||6,181||8,073||27,689||27,037|
|Selling, general and administrative||21,218||24,485||86,514||97,412|
|Research and development||15,433||14,410||50,766||69,662|
|Amortization and impairment of intangible assets||10,462||6,525||38,319||24,288|
|Total operating costs and expenses||53,294||53,493||203,288||218,399|
|Loss from operations||(2,963||)||(1,632||)||(40,732||)||(31,569||)|
|Other (expense) income:|
|Interest expense, net||(2,314||)||(2,180||)||(9,074||)||(8,584||)|
|Change in fair value of contingent consideration related to acquisitions||1,241||2,897||676||987|
|Other (expense) income, net||251||(2,129||)||(1,249||)||(4,367||)|
|Total other expense||(822||)||(1,412||)||(9,647||)||(11,964||)|
|Loss before income taxes||(3,785||)||(3,044||)||(50,379||)||(43,533||)|
|(Provision) benefit for income taxes||(369||)||68||(406||)||(2,186||)|
|Net loss per share:|
|Weighted average shares outstanding:|
|SPECTRUM PHARMACEUTICALS, INC.|
|Condensed Consolidated Balance Sheets|
(In thousands, expect per share and par value amounts)
|Cash and cash equivalents||139,741||129,942|
|Accounts receivable, net of allowance for doubtful accounts of $120 and $120, respectively||30,384||70,758|
|Prepaid expenses and other assets||4,206||3,774|
|Total current assets||191,324||222,469|
|Property and equipment, net of accumulated depreciation||918||1,405|
|Intangible assets, net of accumulated amortization||190,335||230,100|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|Accounts payable and other accrued liabilities||56,539||84,994|
|Accrued payroll and benefits||8,188||8,444|
|Drug development liability||259||1,141|
|Acquisition-related contingent obligations||5,227||4,901|
|Total current liabilities||76,343||109,439|
|Drug development liability, less current portion||14,427||14,644|
|Deferred revenue, less current portion||383||—|
|Acquisition-related contingent obligations||1,439||2,441|
|Deferred tax liability||6,779||6,569|
|Other long-term liabilities||7,444||6,088|
|Convertible senior notes||101,548||96,298|
|Commitments and contingencies|
|Preferred stock, $0.001 par value; 5,000,000 shares authorized|
|Series B Junior Participating Preferred Stock, $0.001 par value; 1,500,000 shares authorized: no shares issued and outstanding||—||—|
|Series E Convertible Voting Preferred Stock, $0.001 par value and $10,000 stated value; 2,000 shares authorized; 20 shares issued and outstanding at December 31, 2015 and 2014, respectively (convertible into 40,000 shares of common stock, with aggregate liquidation value of $240)||123||123|
|Common stock, $0.001 par value; 175,000,000 shares authorized; 68,228,935 and 65,969,699 issued and outstanding at December 31, 2015 and 2014, respectively||68||66|
|Additional paid-in capital||552,108||538,553|
|Accumulated other comprehensive loss||(5,319||)||(850||)|
|Total stockholders’ equity||212,857||254,554|
|Total liabilities and stockholders’ equity||421,220||490,033|
Non-GAAP Financial Measures
In this press release, Spectrum reports certain historical and expected non-GAAP results. Non-GAAP financial measures are reconciled to the most directly comparable GAAP financial measure in the tables of this press release and the accompanying footnotes. The non-GAAP financial measures contained herein are a supplement to the corresponding financial measures prepared in accordance with generally accepted accounting principles (GAAP). The non-GAAP financial measures presented exclude the items summarized in the below table. Management believes that adjustments for these items assist investors in making comparisons of period-to-period operating results and that these items are not indicative of the Company's on-going core operating performance.
Management uses non-GAAP net income (loss) in its evaluation of the Company's core after-tax results of operations and trends between fiscal periods and believes that these measures are important components of its internal performance measurement process. Management believes that providing these non-GAAP financial measures allows investors to view the Company's financial results in the way that management views the financial results.
The non-GAAP financial measures presented herein have certain limitations in that they do not reflect all of the costs associated with the operations of the Company's business as determined in accordance with GAAP. Therefore, investors should consider non-GAAP financial measures in addition to, and not as a substitute for, or as superior to, measures of financial performance prepared in accordance with GAAP. The non-GAAP financial measures presented by the Company may be different from the non-GAAP financial measures used by other companies.
|SPECTRUM PHARMACEUTICALS, INC.|
|Reconciliation of Non-GAAP Adjustments for Condensed Consolidated Statements of Operations|
(In thousands, expect per share amounts)
Three Months Ended
|GAAP product sales, net & license fees and service revenue||$||50,331||$||51,861||$||162,556||$||186,830|
|Non GAAP adjustments to product sales, net & license fees and service revenue:||(15,000||)||—||(24,681||)||—|
|Total adjustments to product sales, net & license fees and service revenues||(15,000||)||—||(24,681||)||—|
|Non-GAAP product sales & license and contract revenue||35,331||51,861||137,875||186,830|
|GAAP cost of product sales (excludes amortization of intangible assets)||6,181||8,073||27,689||27,037|
|Non-GAAP adjustments to cost of product sales||—||—||—||—|
|Non-GAAP cost of product sales (excludes amortization of intangible assets)||6,181||8,073||27,689||27,037|
|GAAP selling, general and administrative expenses||21,218||24,485||86,514||97,412|
|Non GAAP adjustments to SG&A:|
|Shareholder lawsuit expenses||(15||)||(136||)||(7||)||(1,503||)|
|Insurance reimbursement under D&O policy||—||—||2,111||—|
|Total adjustments to SG&A||(3,113||)||(3,090||)||(8,636||)||(12,549||)|
|Non-GAAP selling, general and administrative||18,105||21,395||77,878||84,863|
|GAAP research and development||15,433||14,410||50,766||69,662|
|Non-GAAP adjustments to R&D:|
|Beleodaq milestone cash payment & stock issuance||—||—||—||(17,790||)|
|Other R&D milestone payments||—||—||(3,000||)||—|
|Total adjustments to R&D||(669||)||(402||)||(5,053||)||(19,618||)|
|Non-GAAP research and development||14,764||14,008||45,713||50,044|
|GAAP amortization and impairment of intangible assets||10,462||6,525||38,319||24,288|
|Non-GAAP adjustments to amortization and impairment of intangible assets:|
|Impairment of FUSILEV distribution rights||—||—||(7,160||)||—|
|Total adjustments to amortization and impairment of intangibles||(10,462||)||(6,525||)||(38,319||)||(24,288||)|
|Non-GAAP amortization and impairment of intangibles||—||—||—||—|
|GAAP loss from operations||(2,963||)||(1,632||)||(40,732||)||(31,569||)|
|Non-GAAP adjustments to loss from operations||(756||)||
|Non-GAAP (loss) income from operations||(3,719||)||8,385||(13,405||)||24,886|
|GAAP total other expenses, net||(822||)||(1,412||)||(9,647||)||(11,964||)|
|Realized gain on TopoTarget shares||—||—||—||(2,219||)|
|Market-to-market of contingent consideration||(1,241||)||(2,897||)||(676||)||(987||)|
|Loss on foreign currency exchange||(161||)||2,186||889||6,824|
|Accretion of discount on 2018 Convertible Notes||1,356||1,261||5,250||4,818|
|Total adjustments to other expense, net||(46||)||550||5,463||8,436|
|Non-GAAP total other expenses, net||(868||)||(862||)||(4,184||)||(3,528||)|
|GAAP (provision) benefit for income taxes||(369||)||68||(406||)||(2,186||)|
|Adjustment to (provision) benefit for income taxes||369||(68||)||406||2,186|
|Non-GAAP (provision) benefit for income taxes||—||—||—||—|
|GAAP net loss||(4,154||)||(2,976||)||(50,785||)||(45,719||)|
|Total non-GAAP adjustments||(433||)||10,499||33,196||67,077|
|Non-GAAP net (loss) income||$||(4,587||)||$||7,523||$||(17,589||)||$||21,358|
|Non-GAAP (loss) income per share:|
|Weighted average shares outstanding:|